Risk Factors for the Development and Progression of Diabetic Kidney Disease in Patients with Type 2 Diabetes Mellitus and Advanced Diabetic Retinopathy

다국어 초록 (Multilingual Abstract)

Background: Some patients with type 2 diabetes mellitus (T2DM) do not develop diabetic kidney disease (DKD) despite the presence of advanced diabetic retinopathy (DR). We aimed to investigate the presence of DKD and its risk factors in patients with T2DM and advanced DR.
Methods: We conducted a cross-sectional study in 317 patients with T2DM and advanced DR. The phenotypes of DKD were divided into three groups according to the urine albumin/creatinine ratio (uACR, mg/g) and estimated glomerular filtration rate (eGFR, mL/min/1.73 m2): no DKD (uACR <30 and eGFR ≥60), non-severe DKD (uACR ≥30 or eGFR <60), and severe DKD (uACR ≥30 and eGFR <60). Mean systolic and diastolic blood pressure, mean glycosylated hemoglobin (HbA1c) level, and HbA1c variability (standard deviation [SD] of serial HbA1c values or HbA1c-SD) were calculated for the preceding 2 years.
Results: The prevalence of no DKD, non-severe DKD, and severe DKD was 37.2% (n=118), 37.0% (n=117), and 25.8% (n=82), respectively. HbA1c-SD and the triglyceride/high density lipoprotein cholesterol (TG/HDL-C) ratio correlated positively with uACR and negatively with eGFR. Multiple linear regression analyses showed that the HbA1c-SD and TG/HDL-C ratio were significantly related with eGFR. Multiple logistic regression analyses after adjusting for several risk factors showed that HbA1c-SD and the TG/HDL-C ratio were significant risk factors for severe DKD.
Conclusion: The prevalence of DKD was about 60% in patients with T2DM and advanced DR. HbA1c variability and TG/HDLC ratio may affect the development and progression of DKD in these patients.

참고문헌 (Reference)

1 Levey AS, "Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate" 145 : 247-254, 2006

2 Luk AO, "Risk association of HbA1c variability with chronic kidney disease and cardiovascular disease in type 2 diabetes:prospective analysis of the Hong Kong Diabetes Registry" 29 : 384-390, 2013

3 Fong DS, "Retinopathy in diabetes" 27 (27): S84-S87, 2004

4 Rizzo MR, "Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition" 35 : 2076-2082, 2012

5 Penno G, "Rate and determinants of association between advanced retinopathy and chronic kidney disease in patients with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian multicenter study" 35 : 2317-2323, 2012

6 Wilkinson CP, "Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales" 110 : 1677-1682, 2003

7 Attman PO, "Progression of renal failure and lipids: is there evidence for a link in humans?" 13 : 545-547, 1998

8 Morton J, "Low HDL cholesterol and the risk of diabetic nephropathy and retinopathy: results of the ADVANCE study" 35 : 2201-2206, 2012

9 Vaziri ND, "Lipotoxicity and impaired high density lipoproteinmediated reverse cholesterol transport in chronic kidney disease" 20 (20): S35-S43, 2010

10 Weinberg JM, "Lipotoxicity" 70 : 1560-1566, 2006

11 Ihnat MA, "Hypothesis: the ‘metabolic memory’, the new challenge of diabetes" 24 : 582-586, 2007

12 Tabet F, "High-density lipoproteins, inflammation and oxidative stress" 116 : 87-98, 2009

13 Chang YH, "High-density lipoprotein cholesterol and the risk of nephropathy in type 2 diabetic patients" 23 : 751-757, 2013

14 Lee IT, "High triglyceride-to-HDL cholesterol ratio associated with albuminuria in type 2 diabetic subjects" 27 : 243-247, 2013

15 Hsu CC, "HbA1c variability is associated with microalbuminuria development in type 2 diabetes: a 7-year prospective cohort study" 55 : 3163-3172, 2012

16 Penno G, "HbA1c variability as an independent correlate of nephropathy, but not retinopathy, in patients with type 2 diabetes:the Renal Insufficiency And Cardiovascular Events (RIACE)Italian multicenter study" 36 : 2301-2310, 2013

17 Sugawara A, "HbA(1c)variability and the development of microalbuminuria in type 2diabetes: Tsukuba Kawai Diabetes Registry 2" 55 : 2128-2131, 2012

18 Nalysnyk L, "Glycaemic variability and complications in patients with diabetes mellitus: evidence from a systematic review of the literature" 12 : 288-298, 2010

19 Ansquer JC, "Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS)" 45 : 485-493, 2005

20 Magri CJ, "Factors associated with diabetic nephropathy in subjects with proliferative retinopathy" 44 : 197-206, 2012

21 Davis TM, "Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study" 54 : 280-290, 2011

22 Molitch ME, "Diabetic nephropathy" 26 (26): S94-S98, 2003

23 Tuttle KR, "Diabetic kidney disease: a report from an ADA Consensus Conference" 37 : 2864-2883, 2014

24 Beckman JA, "Diabetes and atherosclerosis:epidemiology, pathophysiology, and management" 287 : 2570-2581, 2002

25 Matsumoto A, "Detection of the association between a deletion polymorphism in the gene encoding angiotensin Iconverting enzyme and advanced diabetic retinopathy" 50 : 195-202, 2000

26 Kramer CK, "Concordance of retinopathy and nephropathy over time in type 1 diabetes: an analysis of data from the Diabetes Control and Complications Trial" 30 : 1333-1341, 2013

27 Kim DM, "An implication of hypertriglyceridemia in the progression of diabetic nephropathy in metabolically obese, normal weight patients with type 2 diabetes mellitus in Korea" 66 (66): S169-S172, 2004

28 Monnier L, "Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes" 295 : 1681-1687, 2006

29 Waden J, "A1C variability predicts incident cardiovascular events, microalbuminuria, and overt diabetic nephropathy in patients with type 1 diabetes" 58 : 2649-2655, 2009

30 Kilpatrick ES, "A1C variability and the risk of microvascular complications in type 1 diabetes: data from the Diabetes Control and Complications Trial" 31 : 2198-2202, 2008